Bristol-Myers Squibb (NYSE:BMY) Holdings Lifted by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company grew its holdings in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 1.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,711,074 shares of the biopharmaceutical company's stock after acquiring an additional 29,480 shares during the period. The Manufacturers Life Insurance Company owned about 0.08% of Bristol-Myers Squibb worth $88,531,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in BMY. Kennedy Capital Management LLC acquired a new position in shares of Bristol-Myers Squibb during the first quarter worth $2,588,000. Hancock Whitney Corp boosted its position in Bristol-Myers Squibb by 5.9% in the 1st quarter. Hancock Whitney Corp now owns 24,555 shares of the biopharmaceutical company's stock valued at $1,332,000 after buying an additional 1,365 shares during the last quarter. LRI Investments LLC acquired a new stake in shares of Bristol-Myers Squibb during the first quarter valued at about $157,000. Atria Investments Inc increased its position in shares of Bristol-Myers Squibb by 13.3% during the first quarter. Atria Investments Inc now owns 138,838 shares of the biopharmaceutical company's stock worth $7,536,000 after acquiring an additional 16,270 shares during the last quarter. Finally, First City Capital Management Inc. lifted its stake in shares of Bristol-Myers Squibb by 4.6% in the first quarter. First City Capital Management Inc. now owns 26,732 shares of the biopharmaceutical company's stock worth $1,450,000 after acquiring an additional 1,171 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company's stock.

Insider Activity at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat purchased 1,830 shares of the firm's stock in a transaction dated Friday, November 1st. The stock was bought at an average price of $54.67 per share, with a total value of $100,046.10. Following the completion of the purchase, the executive vice president now owns 62,109 shares in the company, valued at $3,395,499.03. This trade represents a 3.04 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Phil M. Holzer sold 700 shares of Bristol-Myers Squibb stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $55.62, for a total transaction of $38,934.00. Following the sale, the senior vice president now owns 11,760 shares in the company, valued at approximately $654,091.20. This represents a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.09% of the stock is owned by insiders.

Bristol-Myers Squibb Stock Performance

NYSE BMY traded up $0.53 during trading hours on Thursday, hitting $59.27. The company had a trading volume of 7,061,449 shares, compared to its average volume of 14,301,619. Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $61.08. The firm has a market cap of $120.21 billion, a P/E ratio of -16.51, a price-to-earnings-growth ratio of 15.77 and a beta of 0.44. The company has a quick ratio of 1.09, a current ratio of 1.24 and a debt-to-equity ratio of 2.83. The business has a fifty day simple moving average of $54.41 and a 200-day simple moving average of $48.12.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping analysts' consensus estimates of $1.49 by $0.31. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The business had revenue of $11.89 billion for the quarter, compared to analysts' expectations of $11.26 billion. During the same quarter last year, the company earned $2.00 EPS. The company's revenue for the quarter was up 8.4% compared to the same quarter last year. Equities analysts predict that Bristol-Myers Squibb will post 0.93 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, November 1st. Investors of record on Friday, October 4th were issued a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 4.05%. The ex-dividend date of this dividend was Friday, October 4th. Bristol-Myers Squibb's dividend payout ratio (DPR) is -66.85%.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on BMY shares. Cantor Fitzgerald restated a "neutral" rating and set a $50.00 price objective on shares of Bristol-Myers Squibb in a research note on Friday, October 18th. Daiwa America raised shares of Bristol-Myers Squibb from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, November 13th. Barclays upped their price target on shares of Bristol-Myers Squibb from $42.00 to $43.00 and gave the company an "underweight" rating in a report on Monday, October 7th. Daiwa Capital Markets raised shares of Bristol-Myers Squibb from a "neutral" rating to an "outperform" rating in a report on Wednesday, November 13th. Finally, Leerink Partners raised shares of Bristol-Myers Squibb from a "market perform" rating to an "outperform" rating and boosted their target price for the stock from $55.00 to $73.00 in a research report on Tuesday, November 12th. Two investment analysts have rated the stock with a sell rating, fourteen have given a hold rating, two have issued a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $54.07.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.